Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4046014 | 0.98 | TDP2 (0.31) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL668836 | 0.69 | BRD4 (0.38) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL2418026 | 0.69 | — | — | |
| SCHEMBL26103905 | 0.69 | TDP2 (0.32) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL27713894 | 0.68 | BRD4 (0.37) | TDP2NSD2ABL1PLCG1CES1 | |
| Hydrochloric Acid SCHEMBL27167121 | 0.68 | BRD4 (0.37) | TDP2NSD2ABL1PLCG1CES1 | |
| Hydrochloric Acid SCHEMBL27167119 | 0.68 | BRD4 (0.37) | TDP2NSD2ABL1PLCG1CES1 | |
| Hydrochloric Acid SCHEMBL6225230 | 0.68 | — | — | |
| SCHEMBL670066 | 0.67 | BRD4 (0.36) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL10809791 | 0.66 | PDE3B (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104151311-B | One class fused ring compound or its pharmaceutically acceptable salt and its preparation method and application | 华中师范大学 | 2017-01-04 | — | — | CN | claimed |
| CN-104151311-A | Fused ring compound or pharmaceutically acceptable salt thereof as well as preparation method and application of fused ring compound | UNIV HUAZHONG NORMAL | 2014-11-19 | — | — | CN | claimed |
| CN-121735963-A | Deep sea naphthyridine pyran alkaloid compound and application thereof in preparation of medicines for preventing or treating bone metabolic diseases | 自然资源部第三海洋研究所 | 2026-03-27 | — | — | CN | disclosed |
| EP-4678634-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| CN-115362155-B | Arylamine derivative, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-105164157-B | Modified asymmetric antibodies to FC-receptor binding and methods of use | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117843633-A | Sulfoximine compounds, pharmaceutical compositions and uses thereof | 上海海和药物研究开发股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116710476-A | Determination for fixed dose combinations | 豪夫迈·罗氏有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023076866-A1 | TRICYCLIC SULFOXIMINE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-110256567-B | Method for selecting and generating a customized targeting entity comprising at least two different binding entities and use thereof | 弗·哈夫曼-拉罗切有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115362155-A | Arylamine derivatives, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-2249829-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | Schraermeyer, Ulrich (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010041194-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009104147-A2 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009090081-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | SCHRAERMEYER ULRICH (DE) | 2009-07-23 | — | — | WO | disclosed |
| CN-1250546-C | Tetrahydropyrido compound | ALTANA PHARMA (DE) | 2006-04-12 | — | — | CN | disclosed |
| EP-1561753-A2 | Benzo[b]chromenonapthyridin-7-one and pyrano[2',3':7,8]quino[2,3-b]Quinoxalin-7-one derivatives, process of synthesis, pharmaceutical compositions and their antitumoral properties for the treatment of cancer | Les Laboratoires Servier (FR) | 2005-08-10 | — | — | EP | disclosed |
| CN-1508136-A | Tetrahydropyrido compound | ��̹��ҽҩ��˾ | 2004-06-30 | — | — | CN | disclosed |
| EP-1430052-A2 | SUBSTITUTED IMIDAZO 1, 2-A]-5, 6, 7,8-TETRAHYDROPYRIDINE-8-ONES, METHOD FOR THEIR PRODUCTION AND THE USE THEREOF FOR PRODUCING IMIDAZO 1, 2-A]PYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024963-A2 | SUBSTITUTED IMIDAZO[1, 2-A]-5, 6, 7,8-TETRAHYDROPYRIDINE-8-ONES, METHOD FOR THEIR PRODUCTION AND THE USE THEREOF FOR PRODUCING IMIDAZO[1, 2-A]PYRIDINES | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | WO | disclosed |